Are you considering human biospecimens to evaluate lead candidates prior to first-in-human studies? In this published report in Clinical and Translational Immunology, Biogen scientists did exactly that. Partnering with Sanguine to collect whole blood from diseased patients, they confirmed target engagement and MoA of a novel BTK inhibitor, building confidence for the subsequent phase 1 trial. I'd like to hear from you on whether we can do the same for your research programs.
Warm Regards,
Scott O'Donnell Account Executive Sanguine Bio | Massachusetts
